SCHEMBL2600693

SCHEMBL2600693

C[C@@H](Cc1ccccc1)[C@H]1CO1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 5/20 0.47
TAAR1 Q96RJ0 4/20 0.47
SLC6A2 P23975 2/20 0.47
MAOA P21397 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
CYP2A6 P11509 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA1 P30542 1/20 0.47
SLC18A2 Q05940 1/20 0.44
CYP2D6 P10635 1/20 0.44
TRPA1 O75762 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CHRM2 P08172 2/20 0.41
CHRM4 P08173 2/20 0.41
CHRM5 P08912 2/20 0.41
CHRM1 P11229 2/20 0.41
CHRM3 P20309 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12103354 1.00 SIGMAR1 (0.47) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL12621036 1.00 SIGMAR1 (0.47) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL2600702 1.00 SIGMAR1 (0.47) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL13534760 1.00 SIGMAR1 (0.47) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL13537546 1.00 SIGMAR1 (0.47) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL6840473 1.00 SIGMAR1 (0.47) SIGMAR1TAAR1SLC6A2MAOASLC6A4
Dimethylamine SCHEMBL29014940 0.94 SIGMAR1 (0.48) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL29014928 0.85 AGXT (0.40) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL19320786 0.84 LTA4H (0.50) SIGMAR1SLC6A2MAOASLC6A3MEN1
SCHEMBL8613025 0.82 HTR6 (0.44) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096541-B2 Inhibition of memapsin 1 cleavage in the treatment of diabetes OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2015-08-04 US disclosed
US-8829208-B2 Process for the preparation of darunavir and darunavir intermediates MAPI PHARMA LTD. (IL) 2014-09-09 US disclosed
US-8653141-B2 HIV protease inhibiting compounds ABBVIE INC. (US) 2014-02-18 US disclosed
US-20130261052-A1 INHIBITION OF MEMAPSIN 1 CLEAVAGE IN THE TREATMENT OF DIABETES OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2013-10-03 US disclosed
US-20130116457-A1 CLEAN, HIGH-YIELD PREPARATION OF S,S AND R,S AMINO ACID ISOSTERES AEROJET FINE CHEMICALS LLC (US) 2013-05-09 US disclosed
US-20130096317-A1 REDUCTION OF ALDEHYDES AND KETONES TO ALCOHOLS GEORGIA TECH RESEARCH CORPORATION (US) 2013-04-18 US disclosed
US-20130023463-A1 HIV PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 2013-01-24 US disclosed
US-20120296101-A1 PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES MAPI PHARMA LIMITED (IL) 2012-11-22 US disclosed
US-8163933-B2 Clean, high-yield preparation of S,S and R,S amino acid isosteres AMPAC FINE CHEMICALS LLC (US) 2012-04-24 US disclosed
US-20090012303-A1 CLEAN, HIGH-YIELD PREPARATION OF S,S AND R,S AMINO ACID ISOSTERES AEROJET FINE CHEMICALS LLC (US) 2009-01-08 US disclosed
US-7309803-B2 Clean, High-yield preparation of S,S and R,S amino acid isosteres AEROJET FINE CHEMICALS LLC (US) 2007-12-18 US disclosed
US-7189864-B2 Method of preparing intermediates useful in synthesis of retroviral protease inhibitors G.D. SEARLE & CO. (US) 2007-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023463-A1 HIV PROTEASE INHIBITING COMPOUNDS SERPINB1, HPN, DNPEP SIGMAR1 4397/4885TAAR1 4873/4885SLC6A2 4348/4885
US-20090012303-A1 CLEAN, HIGH-YIELD PREPARATION OF S,S AND R,S AMINO ACID ISOSTERES SRMS, HCK, BHMT2 SIGMAR1 1912/4885TAAR1 2357/4885SLC6A2 3986/4885
US-20130096317-A1 REDUCTION OF ALDEHYDES AND KETONES TO ALCOHOLS POF1B, PHF2, ADH1C SIGMAR1 3352/4885TAAR1 334/4885SLC6A2 4080/4885
US-20130261052-A1 INHIBITION OF MEMAPSIN 1 CLEAVAGE IN THE TREATMENT OF DIABETES MMEL1, ERMP1, ERAP1 SIGMAR1 4660/4885TAAR1 4278/4885SLC6A2 3362/4885
US-20130116457-A1 CLEAN, HIGH-YIELD PREPARATION OF S,S AND R,S AMINO ACID ISOSTERES SRMS, HCK, BHMT2 SIGMAR1 1912/4885TAAR1 2357/4885SLC6A2 3986/4885
US-20120296101-A1 PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES CYP3A43, CYP3A4, DHPS SIGMAR1 675/4885TAAR1 4509/4885SLC6A2 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.